CMMBChemomab Therapeutics Ltd.
Earnings
When Chemomab Therapeutics Ltd. reports, what it reported each quarter, and how the stock took the results.
20 quarters. Mar 31, 2019 to Jun 30, 2025. mixed units.
Latest results
- Revenue
- —
- —
- Net income
- -$8.75M
- N/M
- EPS
- $0.04
- +81.8%
- Revenue
- —
- —
- Net income
- -$8.27M
- N/M
- EPS
- —
- —
- Revenue
- —
- —
- Net income
- -$8.08M
- N/M
- EPS
- $0.04
- +169.2%
- Revenue
- —
- —
- Net income
- -$6.19M
- N/M
- EPS
- $0.03
- +107.7%
All quarters
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2025 | ||||||||||
| Q2 2025 | Jun 30, 2025 | — | — | — | — | — | — | — | — | |
| FY 2024 | ||||||||||
| Q2 2024 | Jun 30, 2024 | — | — | — | — | — | — | $0.01 | — | |
| FY 2023 | ||||||||||
| Q2 2023 | Jun 30, 2023 | — | — | — | — | — | — | $0.04 | — | |
| Q1 2023 | Mar 31, 2023 | May 11, 2023 · pre-market | May 11, 2023 | 41 d | 10-Q | — | — | $0.04 | 0.0% | |
| FY 2022 | ||||||||||
| Q4 2022derived | Dec 31, 2022 | Feb 21, 2023 · pre-market | Mar 20, 2023 | 79 d | 10-K | — | — | — | +16.8% | |
| Q3 2022 | Sep 30, 2022 | — | Nov 10, 2022 | 41 d | 10-Q | — | — | $0.04 | 1.0% | |
| Q2 2022 | Jun 30, 2022 | Aug 12, 2022 · pre-market | Aug 12, 2022 | 43 d | 10-Q | — | — | $0.03 | +14.3% | |
| Q1 2022 | Mar 31, 2022 | May 12, 2022 · pre-market | May 12, 2022 | 42 d | 10-Q | — | — | $0.02 | — | |
| FY 2021 | ||||||||||
| Q4 2021derived | Dec 31, 2021 | Mar 9, 2022 · pre-market | Mar 30, 2022 | 89 d | 10-K | — | — | — | — | |
| Q3 2021 | Sep 30, 2021 | Nov 12, 2021 · pre-market | Nov 12, 2021 | 43 d | 10-Q | — | — | $0.01 | +2.0% | |
| Q2 2021 | Jun 30, 2021 | Aug 13, 2021 · pre-market | Aug 13, 2021 | 44 d | 10-Q | — | — | $0.01 | 8.2% | |
| Q1 2021 | Mar 31, 2021 | May 13, 2021 · market hours | May 13, 2021 | 43 d | 10-Q | — | — | $0.01 | 3.3% | |
| FY 2020 | ||||||||||
| Q4 2020derived | Dec 31, 2020 | — | Mar 9, 2021 | 68 d | 10-K | — | — | — | — | |
| Q3 2020 | Sep 30, 2020 | — | Nov 16, 2020 | 47 d | 10-Q | — | — | $0.01 | — | |
| Q2 2020 | Jun 30, 2020 | — | Aug 14, 2020 | 45 d | 10-Q | — | — | $0.01 | — | |
| Q1 2020 | Mar 31, 2020 | — | May 7, 2020 | 37 d | 10-Q | — | — | $0.01 | — | |
| FY 2019 | ||||||||||
| Q4 2019derived | Dec 31, 2019 | — | Mar 17, 2020 | 77 d | 10-K | — | — | — | — | |
| Q3 2019 | Sep 30, 2019 | — | — | — | — | — | — | -$0.19 | — | |
| Q2 2019 | Jun 30, 2019 | — | — | — | — | — | — | -$0.12 | — | |
| Q1 2019 | Mar 31, 2019 | — | — | — | — | — | — | -$0.38 | — | |
Earlier years, FY 2019 to FY 2022The latest three years
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Source filings
Provenance
ProvenanceData status and checks
Chemomab Therapeutics Ltd. · CIK 1534248 · Engraved from SEC EDGAR